Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., ...

Project Hail Mary author Andy Weir keeps on recommending this sci-fi book everywhere he goes, and it's not hard to understand ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...

With "Project Hail Mary" dominating the box office, author Andy Weir is steering fans toward Blake Crouch’s mind-bending ...

"Anti-AI" stocks are a contrarian bet that the market's tech-fueled rally will be short-lived. It may be time for an anti-AI portfolio. That's because AI-related stocks have been soaring. "Anti-AI" ...

A total of 28 companies joined The Crunchbase Unicorn Board in April, with robotics startups and frontier labs leading by ...

BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law ...

According to Rogers, the computer science faculty use Gradescope’s Measure Of Software Similarity (MOSS) tool to identify ...

Enterprise AI systems can be corrupted through data poisoned by accident, adversaries, or bad hygiene. Most organizations ...

Digital transformation has created vast new opportunities. But that didn’t mean getting rid of everything we already had.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Because Markets Don’t Build Themselves, Bruce Cleveland, CEO of Traction Gap Partners, stresses that most companies don’t fail because their products or services are substandard but because the market ...